Literature DB >> 6193872

Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin.

J L Magnani, Z Steplewski, H Koprowski, V Ginsburg.   

Abstract

Monoclonal antibody 19-9, produced by a hybridoma prepared from spleen cells of a mouse immunized with a human colon carcinoma cell line, detects an antigen in the serum from most patients with gastrointestinal and pancreatic cancer (M. Herlyn, H.F. Sears, Z. Steplewski, and H. Koprowski, J. Clin. Immunol., 2: 135-140, 1982). The epitope of this antibody is a carbohydrate with the sugar sequence (formula; see text) in which NeuNAc is N-acetylneuraminic acid, Gal is galactose, GlcNAc is N-acetylglucosamine, and Fuc is fucose. In the colon carcinoma cell line and many gastrointestinal and pancreatic cancers, this sequence occurs in a monosialoganglioside containing a sialylated Lea-active pentasaccharide (sialylated lacto-N-fucopentaose II, IV3-alpha-NeuNAc-III4-alpha-Fuc-LcOse4, in which LcOse4 is Gal beta 1-3GlcNAc beta 1-3Gal beta 1-4Glc) (J. L. Magnani et al. J. Biol. Chem., 257: 14365-14369, 1982). However, the antigen in the sera of patients occurs mainly as a mucin, not a ganglioside, based on the following evidence. Little antigen is extracted by organic solvents from sera, and that which is extracted remains at the origin under conditions of thin-layer chromatography where the ganglioside antigen migrates up the plate. Upon gel filtration of serum on Sephacryl S-400, the antigen is eluted in the void volume, indicating a molecular weight of greater than or equal to 5 X 10(6). Incubation for 5 hr at 37 degrees in 0.1 N NaOH destroys the serum antigen but does not affect the ganglioside antigen. The density of the serum antigen as determined in a CsCl gradient is 1.50 g/ml, while in 4 M guanidine. HCl its density is 1.43 g/ml. Finally, antigen affinity purified by antibody 19-9 from the serum of a cancer patient belonging to the Le(a-b+) blood group contains Leb antigen, consistent with the multiple antigenic specificities exhibited by mucins.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6193872

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  141 in total

1.  [Clinical value of the CA 19-9 tumor marker with special reference to the Lewis phenotype].

Authors:  G Kolb; F Safi; K Beckh; H G Beger
Journal:  Med Klin (Munich)       Date:  1997-04-15

2.  Tumor cell MUC1 and CD43 are glycosylated differently with sialyl-Lewis a and x epitopes and show variable interactions with E-selectin under physiological flow conditions.

Authors:  J Fernandez-Rodriguez; O Dwir; R Alon; G C Hansson
Journal:  Glycoconj J       Date:  2001 Nov-Dec       Impact factor: 2.916

3.  Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer.

Authors:  Jing-Ting Jiang; Chang-Ping Wu; Hai-Feng Deng; Ming-Yang Lu; Jun Wu; Hong-Yu Zhang; Wen-Hui Sun; Mei Ji
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

4.  Flow cytometric analysis of sialyl Lewis A antigen on human cancer cells by using F(ab')2μ fragments prepared from a mouse IgM monoclonal antibody.

Authors:  K Morimoto; K Inouye
Journal:  Cytotechnology       Date:  1997-09       Impact factor: 2.058

5.  Differential mucin gene expression in human pancreatic and colon cancer cells.

Authors:  S Yonezawa; J C Byrd; R Dahiya; J J Ho; J R Gum; B Griffiths; D M Swallow; Y S Kim
Journal:  Biochem J       Date:  1991-06-15       Impact factor: 3.857

Review 6.  The detection and discovery of glycan motifs in biological samples using lectins and antibodies: new methods and opportunities.

Authors:  Huiyuan Tang; Peter Hsueh; Doron Kletter; Marshall Bern; Brian Haab
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

Review 7.  Simple sugars to complex disease--mucin-type O-glycans in cancer.

Authors:  Matthew R Kudelka; Tongzhong Ju; Jamie Heimburg-Molinaro; Richard D Cummings
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

8.  Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology.

Authors:  Nerissa Therese Viola-Villegas; Samuel L Rice; Sean Carlin; Xiaohong Wu; Michael J Evans; Kuntal K Sevak; Marija Drobjnak; Govind Ragupathi; Ritsuko Sawada; Wolfgang W Scholz; Philip O Livingston; Jason S Lewis
Journal:  J Nucl Med       Date:  2013-09-12       Impact factor: 10.057

9.  Discrimination between adenocarcinoma and normal pancreatic ductal fluid by proteomic and glycomic analysis.

Authors:  Mindy Porterfield; Peng Zhao; Haiyong Han; John Cunningham; Kazuhiro Aoki; Daniel D Von Hoff; Michael J Demeure; J Michael Pierce; Michael Tiemeyer; Lance Wells
Journal:  J Proteome Res       Date:  2013-12-12       Impact factor: 4.466

10.  Glycosphingolipid antigens of Leishmania (Leishmania) amazonensis amastigotes identified by use of a monoclonal antibody.

Authors:  C L Barbiéri; S Giorgio; A J Merjan; E N Figueiredo
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.